Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway.
Aluminum
Alzheimer’s disease
Cilostazol
Neprilysin
Tumor necrosis factor-alpha
cAMP/CREB pathway
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
10
05
2022
accepted:
12
05
2022
pubmed:
22
6
2022
medline:
30
11
2022
entrez:
21
6
2022
Statut:
ppublish
Résumé
The most prevalent type of dementia is Alzheimer's disease (AD), which is currently incurable. Existing treatments for Alzheimer's disease, such as acetylcholinesterase inhibitors, are only effective for symptom relief. Disease-modifying medications for Alzheimer's disease are desperately required, given the enormous burdens that the disease places on individuals and communities. Phosphodiesterase (PDE) inhibitors are gaining a lot of attention in the research community because of their potential in treating age-related cognitive decline. Cilostazol is a selective PDE III inhibitor used as antiplatelet agent through cAMP response element-binding (CREB) protein phosphorylation pathway (cAMP/CREB). The neuroprotective effect of cilostazol in AD-like cognitive decline in rats was investigated in this study. After 2 months of intraperitoneal administration of 10 mg/kg aluminum chloride, Morris water maze and Y-maze (behavioral tests) were performed. After that, histological and biochemical examinations of the hippocampal region were carried out. Aluminum chloride-treated rats showed histological, biochemical, and behavioral changes similar to Alzheimer's disease. Cilostazol improved rats' behavioral and histological conditions, raised neprilysin level while reduced levels of amyloid-beta protein and phosphorylated tau protein. It also decreased the hippocampal levels of tumor necrosis factor-alpha, nuclear factor-kappa B, FAS ligand, acetylcholinesterase content, and malondialdehyde. These outcomes demonstrate the protective activity of cilostazol versus aluminum-induced memory impairment.
Identifiants
pubmed: 35727381
doi: 10.1007/s10787-022-01010-1
pii: 10.1007/s10787-022-01010-1
pmc: PMC9700579
doi:
Substances chimiques
Cilostazol
N7Z035406B
Aluminum Chloride
3CYT62D3GA
Acetylcholinesterase
EC 3.1.1.7
Phosphodiesterase Inhibitors
0
Cyclic AMP Response Element-Binding Protein
0
Phosphoric Diester Hydrolases
EC 3.1.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2477-2488Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Toxicol Ind Health. 2017 Apr;33(4):308-317
pubmed: 27178312
Trends Neurosci. 2010 May;33(5):230-40
pubmed: 20223527
Lancet. 2011 Mar 19;377(9770):1019-31
pubmed: 21371747
J Alzheimers Dis. 2010;22(4):1363-73
pubmed: 20930272
Biol Trace Elem Res. 2015 May;165(1):67-74
pubmed: 25613582
Nat Med. 2000 Feb;6(2):143-50
pubmed: 10655101
Restor Neurol Neurosci. 2008;26(6):467-73
pubmed: 19096134
Biosci Biotechnol Biochem. 2010;74(7):1355-61
pubmed: 20622454
Biol Trace Elem Res. 2015 Dec;168(2):462-71
pubmed: 26018497
Circ Res. 2007 Apr 13;100(7):950-66
pubmed: 17431197
Naunyn Schmiedebergs Arch Pharmacol. 2015 Nov;388(11):1151-61
pubmed: 26142889
J Alzheimers Dis. 2010;19(1):341-53
pubmed: 20061649
Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a000141
pubmed: 20066113
J Neurosci Res. 2014 Feb;92(2):206-17
pubmed: 24254769
J Neuropsychiatry Clin Neurosci. 2007 Fall;19(4):471-2
pubmed: 18070854
J Inorg Biochem. 2005 Sep;99(9):1865-70
pubmed: 16055195
J Neurosci. 2001 Oct 1;21(19):7551-60
pubmed: 11567045
Psychopharmacology (Berl). 2002 Mar;160(3):233-44
pubmed: 11889492
Br J Clin Pharmacol. 2011 Oct;72(4):634-46
pubmed: 21649691
Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2106-13
pubmed: 21680899
J Alzheimers Dis. 2009;17(3):661-80
pubmed: 19581722
Brain Res Brain Res Rev. 2005 Apr;48(2):251-6
pubmed: 15850664
J Biol Chem. 2006 Oct 13;281(41):30471-8
pubmed: 16912050
Am J Pathol. 2007 Jul;171(1):241-51
pubmed: 17591969
PLoS One. 2012;7(9):e45757
pubmed: 23049854
Pharmacol Biochem Behav. 2015 Aug;135:20-30
pubmed: 25987325
Neuroreport. 1994 Sep 8;5(14):1777-80
pubmed: 7827330
J Neurosci Methods. 1984 May;11(1):47-60
pubmed: 6471907
Nutr Neurosci. 2016 Jul;19(6):269-78
pubmed: 25842984
Biochem Biophys Res Commun. 2011 May 20;408(4):602-8
pubmed: 21530492
Neuron. 2009 Apr 16;62(1):42-52
pubmed: 19376066
Br J Pharmacol. 2010 Dec;161(8):1899-912
pubmed: 20825411
Brain Res. 2007 Jul 9;1157:112-20
pubmed: 17521620
Biochem J. 1984 Aug 15;222(1):1-15
pubmed: 6383353
Psychopharmacology (Berl). 2009 Jan;202(1-3):419-43
pubmed: 18709359
Mol Neurobiol. 2016 Apr;53(3):1403-1418
pubmed: 25526861
Int J Biochem Cell Biol. 2005 Feb;37(2):289-305
pubmed: 15474976
Neurobiol Dis. 2005 Jun-Jul;19(1-2):57-65
pubmed: 15837561
Alzheimers Dement (N Y). 2016 Oct 27;2(4):250-257
pubmed: 29067312
Comp Biochem Physiol C Toxicol Pharmacol. 2005 Feb;140(2):251-5
pubmed: 15907769
J Renin Angiotensin Aldosterone Syst. 2013 Jun;14(2):124-36
pubmed: 23060470
J Neurosci. 2008 Aug 13;28(33):8354-60
pubmed: 18701698
Curr Pharm Des. 2006;12(20):2511-23
pubmed: 16842174
J Pharmacol Exp Ther. 2002 Feb;300(2):709-15
pubmed: 11805237
Curr Opin Pharmacol. 2007 Feb;7(1):86-92
pubmed: 17113826
Curr Pharm Des. 2015;21(3):317-31
pubmed: 25159073
Neurosci Lett. 2011 Oct 3;503(2):93-9
pubmed: 21872644
Neurosci Lett. 2018 Jun 11;677:19-25
pubmed: 29684530
Life Sci. 2008 Dec 19;83(25-26):828-35
pubmed: 18983856
Curr Pharm Des. 2006;12(5):565-73
pubmed: 16472148
Cardiovasc Res. 2010 May 1;86(2):211-8
pubmed: 20202975
EMBO J. 1991 Dec;10(12):3805-17
pubmed: 1935902
Mol Cancer Res. 2013 May;11(5):494-505
pubmed: 23386688
Psychopharmacology (Berl). 2016 Mar;233(6):1055-66
pubmed: 26686236
Br J Pharmacol. 2010 Mar;159(6):1274-85
pubmed: 20128801
Stroke. 2006 Jun;37(6):1539-45
pubmed: 16645134
Genes Dev. 2004 Sep 15;18(18):2195-224
pubmed: 15371334
Brain Res. 2007 Dec 14;1185:246-55
pubmed: 17936728
BMC Neurosci. 2013 Mar 11;14:26
pubmed: 23497276
Exp Mol Med. 2006 Aug 31;38(4):333-47
pubmed: 16953112
Neurotoxicol Teratol. 2007 Mar-Apr;29(2):211-8
pubmed: 17197156
Ann Clin Transl Neurol. 2014 Aug;1(8):519-33
pubmed: 25356424
J Neuropathol Exp Neurol. 2007 Aug;66(8):683-6
pubmed: 17882012
Rev Neurosci. 2006;17(5):497-523
pubmed: 17180876
Pharmacol Rep. 2011;63(4):915-23
pubmed: 22001979
Cell Mol Neurobiol. 2012 Apr;32(3):399-407
pubmed: 22090160
J Anat. 2005 Sep;207(3):265-9
pubmed: 16185251
J Neurochem. 2008 Oct;107(1):197-207
pubmed: 18680556
Brain Res Rev. 2006 Sep;52(2):275-92
pubmed: 16782202
Mol Neurobiol. 2017 Apr;54(3):1906-1918
pubmed: 26897372
Transl Res. 2018 Mar;193:31-41
pubmed: 29232559
Hypertension. 2009 Oct;54(4):782-7
pubmed: 19635982
J Neurochem. 1999 Aug;73(2):712-8
pubmed: 10428068
Mol Neurobiol. 2013 Dec;48(3):500-15
pubmed: 23519520
Heart Surg Forum. 2011 Jun;14(3):E171-7
pubmed: 21676683
Ageing Res Rev. 2005 May;4(2):123-40
pubmed: 15964248
Front Aging Neurosci. 2017 Oct 17;9:337
pubmed: 29089887
J Cereb Blood Flow Metab. 2010 Feb;30(2):299-310
pubmed: 19826432